Alto Neuroscience, Inc. 8-K

What Happened
Alto Neuroscience, Inc. filed an 8-K on July 14, 2026 disclosing that on July 13, 2026 it entered into an underwriting agreement to sell 3,776,436 shares of common stock in an underwritten registered direct offering at $26.48 per share. The company estimates net proceeds of approximately $93.9 million after underwriting discounts, commissions and estimated offering expenses. The offering closing was expected to occur on July 14, 2026, subject to customary closing conditions.

Key Details

• Shares offered: 3,776,436 shares of common stock at $26.48 per share.
• Estimated net proceeds: about $93.9 million (after fees and expenses).
• Use of proceeds: to accelerate and expand clinical development of ALTO-207, including a planned additional Phase 3 monotherapy trial for treatment-resistant depression, and for general working capital.
• Managers: BofA Securities, Stifel, William Blair, and Robert W. Baird as joint book-running managers; JonesTrading and H.C. Wainwright as co-managers. Underwriters agreed to reimburse certain offering-related expenses.

Why It Matters
This financing, if completed, would materially increase Alto’s cash resources and is earmarked primarily to fund clinical development of ALTO-207, including an added Phase 3 trial for treatment-resistant depression. For investors, the deal affects share count and dilution and signals the company is prioritizing late-stage clinical investment. The offering is subject to customary closing conditions and contains standard underwriting and indemnification provisions; the filing also includes customary forward-looking statement caution.